



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 08/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known 1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
<i>[initials]</i>	AA	5,077,292	12/31/1991	Gluchowski			
	AB	5,034,406	7/23/1991	Gluchowski			
	AC	5,021,416	6/4/1991	Gluchowski			
	AD	5,130,441	7/14/1992	Gluchowski			
	AE	5,066,664	11/19/1991	Gluchowski			
	AF	5,151,440	9/29/1992	Gluchowski			
	AG	5,112,822	5/12/1992	Gluchowski			
	AH	5,091,528	2/25/1992	Gluchowski			
	AI	5,231,096	7/27/1993	Gluchowski			
	AJ	5,198,442	3/30/1993	Gluchowski			
	AK	5,580,892	12/3/1996	Garst et al			
	AL	5,552,403	9/3/1996	Burke et al			
	AM	5,663,189	9/2/1997	Maurer et al			
	AN	5,215,991	6/1/1993	Burke et al			
	AO	5,180,721	1/19/1993	Burke et al			
	AP	5,561,132	10/1/1996	Burke et al			
	AQ	5,621,113	4/15/1997	Boyd et al			
	AR	RE 32,400	4/1987	Karjalainen et al	574	397	
	AS	4,443,466	4/1984	Karjalainen et al	424	277	
	AT	4,496,572	1/1985	Cross et al	574	337	
	AU	4,540,705	9/1985	Bailey	574	401	
	AV	5,151,526	9/1992	Hsu et al	548	3151 X	
	AW	5,750,720	5/1998	Boyd et al II	578	3151	

EXAMINER *[Signature]* DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[Signature]

11/3/04



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 09/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known 1626

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
EX	AX	0 194 984	9/17/1986	EPO			
PH	AY	0 304 910	3/1/1989	EPO			
PH	BB	WO 97/35858	10/2/1997	WIPO PCT			
PH	BC	WO 97/31636	9/4/1997	WIPO PCT			
PH	BD	WO 95/19968	7/27/1995	WIPO PCT			
PH	BE	WO 97/03079	1/30/1997	WIPO PCT			
PH	BF	WO 97/15302	5/1/1997	WIPO PCT			
PH	BG	WO 95/16449	6/22/1995	WIPO PCT			
PH	BH	WO 97/12874	4/10/1997	WIPO PCT OREON			
PH	BI	WO 94/07866	4/14/1994	WIPO PCT TOLYO			
PH	BJ	WO 96/01813	1/15/1996	WIPO PCT			
PH	BK	1/242571	9/1989	JAPAN KTHARA			
PH	BL	4/267130	1992	JAPAN RTAL			

EXAMINER Floyd W. Ayer

DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Kelvin Jordan

11/13/04



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet 3 of 3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET: 17243CIP3(AP)	SERIAL NO.: 09/815,362
APPLICANT: Chow et al	METHOD OF TREATMENT WITH COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON ALPHA 2B AND/OR 2C
FILING DATE: March 21, 2001	GROUP: Not Known 1626

OTHER PRIOR ART

(Including Author, Title, Date, Pertinent Pages, etc.)

Ph		BM	Bylund et al, 1994, Pharmacol Rev. 46, pp. 121-136, "International Union of Pharmacology Nomenclature of Adrenoceptors"
Ph		BN	Shimizu et al, 1969, J. Neurochem. 16, pages 1609-1619, "A Radiosotopic Method For Measuring The Formation of Adenosine 3', 5' -Cyclic Monophosphate in Incubated Slices Of Brain"
Ph		BO	Messier et al, 1995, Pharmacol. Toxicol. 76, pages 308-311, "High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells"
Ph		BP	Neve et al, 1992, J. Biol. Chem. 267, pages 25748-25753, "Dopamine D2 Receptor Stimulation of Na ⁺ /H ⁺ Exchange Assessed by Quantification of Extracellular Acidification"
Ph		BQ	Williams et al, 1990, J. Auton. Pharmacol, 10, 247, pages 109-118, "α ₂ -adrenoceptor antisecretory responses in the rat jejunum"
Ph		BR	Fondacaro et al, 1988, Vol. 247, No. 2, pages 481-486, "The Journal of Pharmacology and Experimental Therapeutics"
Ph		BS	White et al, 1975, Communications/Synthesis, pages 602-3, "A Convenient Procedure for the Preparation of 2-endo-Hydroxy-cis-bicyclo [3.3.0]octane"
Ph		BT	Conklin et al, Nature, 1993, Vol. 363, pages 274-6, "Substitution of three amino acids switches receptor specificity of G _q α to that of G ₁ α"
Ph		BU	Schaaf et al, J. Med. Chem. 1983, Vol. 26, pages 328-334, "Structure-Activity Studies of Configurationally Rigid Arylprostaglandins"
Ph		BV	Kihara et al, "Preparation of imidazole derivatives as drugs", 6001 Chemical Abstracts, Columbus, Ohio, U.S. Vol. 112 (4/9/1996), No. 16, XP-002098179
Ph		BW	Zhang et al, "Medetomidine Analogs as α ₂ -Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α ₂ -Adrenoceptors Involving a 'Methyl Pocket' ", J. Med. Chem. 1997, 40. pgs. 3014-3024

EXAMINER Theresa D. Hagedorn

DATE CONSIDERED 09-18-2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1113/04